Episode 59: ASM Roundup - Day 2 with Dr. Marinka Twilt and Dr. Mo Osman

Hosts: Dr. Daniel Ennis, Dr. Janet Pope Guests: Dr. Marinka Twilt (Pediatric Rheumatologist, University of Calgary; ASM Program Committee Chair), Dr. Mo Osman (University of Alberta; Abstract Chair & ASM Planning Committee Co-Chair) We’re coming to you almost live from Halifax for Day 2 of the Canadian Rheumatology Association ASM. The day featured diverse podium science, practical workshops, and a lively Great Debate on DMARD tapering. Podium sessions highlighted lupus research on cancer risk, rising costs and work disability in RA, and new biologic insights into flares, with B-cell changes supporting patient-reported disease activity in lupus. Workshops focused on practical tools, including capillaroscopy for early CTD detection, pediatric updates on neonatal lupus risk (anti-Ro vs anti-La), and a structured lab-based approach to unexplained lymphadenopathy. The Dunlop-Dottridge Lecture reviewed statin-associated myositis, emphasizing delayed onset, persistence after discontinuation of the statins, and early IVIG-based treatment. The Great Debate explored DMARD tapering, reinforcing that while guidelines are cautious, real-world care requires shared decision-making and a focus on the lowest effective dose rather than full discontinuation. Main Takeaways Rising costs and ongoing work disability remain significant in RA Patient-reported flares have a clear biological basis Statin-associated myositis can occur years after statin use and requires early IVIG DMARD tapering should be individualized, with focus on lowest effective dose What to Watch for on Day 3 State-of-the-art lecture on Still’s disease across the lifespan More high-impact podium presentations Clinical workshops, including one on topical therapies Gala dinner and closing events More highlights coming tomorrow—stay tuned!